{"id":907960,"date":"2025-11-10T19:48:39","date_gmt":"2025-11-11T00:48:39","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/visionary-holdings-nasdaq-gv-launches-stem-cell-based-anti-aging-product-line-accelerating-expansion-into-asias-premium-regenerative-medicine-market\/"},"modified":"2025-11-10T19:48:39","modified_gmt":"2025-11-11T00:48:39","slug":"visionary-holdings-nasdaq-gv-launches-stem-cell-based-anti-aging-product-line-accelerating-expansion-into-asias-premium-regenerative-medicine-market","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/visionary-holdings-nasdaq-gv-launches-stem-cell-based-anti-aging-product-line-accelerating-expansion-into-asias-premium-regenerative-medicine-market\/","title":{"rendered":"Visionary Holdings (Nasdaq: GV) Launches Stem Cell-Based Anti-Aging Product Line, Accelerating Expansion into Asia&#8217;s Premium Regenerative Medicine Market"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">HONG KONG<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Nov. 10, 2025<\/span><\/span> \/PRNewswire\/ &#8212;\u00a0<i>Visionary Holdings Inc.<\/i> (&#8220;GV&#8221; or the &#8220;Company&#8221;), a technology-driven multinational enterprise listed on Nasdaq (Nasdaq: GV), today announced that its wholly owned subsidiary, <b>Visionary Health Technology Group Limited<\/b>, has official launch of its <b>medical-grade stem cell anti-aging product line<\/b>, initially targeting the Chinese mainland and broader Asian markets.<\/p>\n<p>This launch marks a major milestone following\u00a0GV&#8217;s entry into the stem cell and medical aesthetics sector earlier this year, as well as its <b>strategic partnership and global technology licensing agreement<\/b> with <b>Jiangsu Yike Regenerative Medicine Co., Ltd. (&#8220;Yike&#8221;)<\/b>, advancing the Company&#8217;s commercialization in regenerative medicine.<\/p>\n<p>\n        <b>Core Product Lines and Innovative Value Model<\/b>\n      <\/p>\n<p>GV&#8217;s anti-aging product portfolio includes three major categories:<\/p>\n<ul type=\"disc\">\n<li>\n          <b>Comprehensive Regenerative Package<\/b> \u2014 the flagship <i>Life Rejuvenation Program<\/i>, combining mesenchymal stem cells, NK cell therapy, and AI-based diagnostics, designed for entrepreneurs and high-net-worth individuals.<\/li>\n<li>\n          <b>Precision Repair Package<\/b>\u00a0\u2014 integrating targeted stem cell therapy and DFPP blood purification for clients with specific degenerative or chronic conditions.<\/li>\n<li>\n          <b>Premium Personalized Program<\/b> \u2014 including full-genome sequencing, dual-institution medical consultations, and annual customized health management for ultra-high-net-worth clients.<\/li>\n<\/ul>\n<p>This product launch marks GV&#8217;s next operational milestone following its global licensing agreement with Yike, transitioning from R&amp;D collaboration to tangible market implementation. GV has integrated Yike&#8217;s proprietary regenerative technologies into a full suite of personalized anti-aging and cellular rejuvenation solutions, covering stem cell therapy, NK cell revitalization, AI-based health assessment, and nano-delivery systems.<\/p>\n<p>The new products will be operated through GV&#8217;s <span class=\"xn-location\">Asia-Pacific<\/span> headquarters in <span class=\"xn-location\">Hong Kong<\/span>, initially launching across <span class=\"xn-location\">Hong Kong<\/span>, <span class=\"xn-location\">Singapore<\/span>, and the Chinese mainland to provide premium, customized health solutions for high-end clients.<\/p>\n<p>GV plans to advance its commercialization strategy through the following initiatives:<\/p>\n<ul type=\"disc\">\n<li>\n          <b>Establish a joint venture production and clinical application base<\/b> to enable localized manufacturing and validation of stem cell products;<\/li>\n<li>\n          <b>Build a cross-border sales and distribution network<\/b> covering mainland <span class=\"xn-location\">China<\/span>, <span class=\"xn-location\">Hong Kong<\/span>, and <span class=\"xn-location\">Southeast Asia<\/span>, while expanding into <b><span class=\"xn-location\">Canada<\/span>, <span class=\"xn-location\">the United States<\/span>, and <span class=\"xn-location\">Mexico<\/span><\/b>;<br \/><b><br \/>Partner with premium medical and aesthetic institutions<\/b>\u00a0to jointly develop branded clinics and anti-aging experience center<\/li>\n<\/ul>\n<p>\n        <b>Management Comments<\/b>\n      <\/p>\n<p>\n        <b><br \/>\n          <span class=\"xn-person\">Xiyong Hou<\/span>, CEO of Visionary Holdings<\/b>, commented:<\/p>\n<p>&#8220;The official launch of GV&#8217;s stem cell-based anti-aging products marks an important milestone in transforming our technological assets into tangible commercial value. Since entering into our strategic partnership and global licensing agreement with Yike, GV has successfully advanced from technology development to market-ready products.<\/p>\n<p>As <span class=\"xn-location\">Asia<\/span> continues to be the fastest-growing market for regenerative aesthetics, this launch not only opens new revenue streams for GV but also establishes a solid foundation for our leadership in longevity and cellular rejuvenation technologies. The Company expects this product line to serve as a new driver of profitability in upcoming fiscal years and to further strengthen GV&#8217;s visibility and positioning in the global capital markets.&#8221;<\/p>\n<p>\n        <b>About Visionary Holdings Inc.<\/b>\n      <\/p>\n<p>Visionary Holdings Inc. (Nasdaq: GV) is a technology-driven multinational enterprise focused on innovative education, AI applications, and high-tech healthcare solutions. Headquartered in <span class=\"xn-location\">Toronto, Canada<\/span>, the Company operates through its subsidiaries across <span class=\"xn-location\">North America<\/span> and <span class=\"xn-location\">Asia<\/span>, driving technological advancement, cross-border innovation, and global health transformation.<\/p>\n<p>\n        <b>About Yike Regenerative Medicine<\/b>\n      <\/p>\n<p>Jiangsu Yike Regenerative Medicine (<a href=\"http:\/\/jsyk.club\" target=\"_blank\" rel=\"nofollow\">http:\/\/jsyk.club<\/a>) is a high-tech enterprise specializing in regenerative medicine and precision anti-aging technologies. The company operates across multiple platforms, including genetic engineering, stem cell research, and immune cell applications. Yike co-established the Institute of Aging and Regenerative Medicine with <span class=\"xn-location\">Jinan<\/span> University, and holds numerous international patents and software copyrights. It also maintains ISO9001 and\u00a0cGMP certifications, underscoring its commitment to quality and compliance.<\/p>\n<p>\n        <b>Cautionary Note Regarding Forward-Looking Statements<\/b>\n      <\/p>\n<p>This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as &#8220;will&#8221;, &#8220;expects&#8221;, &#8220;anticipates&#8221;, &#8220;future&#8221;, &#8220;intends&#8221;, &#8220;plans&#8221;, &#8220;believes&#8221;, &#8220;estimates&#8221;, &#8220;target&#8221;, &#8220;going forward&#8221;, &#8220;outlook,&#8221; &#8220;objective&#8221; and similar terms. Such statements are based upon management&#8217;s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and which are beyond GV&#8217;s control, which may cause GV&#8217;s actual results, performance or achievements (including the RMB\/USD value of its anticipated benefit to GV as described herein) to differ materially and in an adverse manner from anticipated results contained or implied in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in GV&#8217;s filings with the U.S. Securities and Exchange Commission, which are available at <a href=\"http:\/\/www.sec.gov\" rel=\"nofollow\">www.sec.gov<\/a>. GV does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.<\/p>\n<p>\n        <b>Contacts:<\/b>\n      <\/p>\n<p>\n        <b>Visionary Holdings Inc.<br \/><\/b>Investor Relations<br \/>Email:\u00a0<a href=\"mailto:IR@visionary.holdings\" target=\"_blank\" rel=\"nofollow\">IR@visionary.holdings<\/a><\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=CN20006&amp;sd=2025-11-10\" \/> View original content:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/visionary-holdings-nasdaq-gv-launches-stem-cell-based-anti-aging-product-line-accelerating-expansion-into-asias-premium-regenerative-medicine-market-302610020.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/visionary-holdings-nasdaq-gv-launches-stem-cell-based-anti-aging-product-line-accelerating-expansion-into-asias-premium-regenerative-medicine-market-302610020.html<\/a><\/p>\n<p>SOURCE  Visionary Holdings<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=CN20006&amp;Transmission_Id=202511100930PR_NEWS_USPR_____CN20006&amp;DateId=20251110\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire HONG KONG , Nov. 10, 2025 \/PRNewswire\/ &#8212;\u00a0Visionary Holdings Inc. (&#8220;GV&#8221; or the &#8220;Company&#8221;), a technology-driven multinational enterprise listed on Nasdaq (Nasdaq: GV), today announced that its wholly owned subsidiary, Visionary Health Technology Group Limited, has official launch of its medical-grade stem cell anti-aging product line, initially targeting the Chinese mainland and broader Asian markets. This launch marks a major milestone following\u00a0GV&#8217;s entry into the stem cell and medical aesthetics sector earlier this year, as well as its strategic partnership and global technology licensing agreement with Jiangsu Yike Regenerative Medicine Co., Ltd. (&#8220;Yike&#8221;), advancing the Company&#8217;s commercialization in regenerative medicine. Core Product Lines and Innovative Value Model GV&#8217;s anti-aging product portfolio includes three major categories: Comprehensive Regenerative Package &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/visionary-holdings-nasdaq-gv-launches-stem-cell-based-anti-aging-product-line-accelerating-expansion-into-asias-premium-regenerative-medicine-market\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Visionary Holdings (Nasdaq: GV) Launches Stem Cell-Based Anti-Aging Product Line, Accelerating Expansion into Asia&#8217;s Premium Regenerative Medicine Market&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-907960","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Visionary Holdings (Nasdaq: GV) Launches Stem Cell-Based Anti-Aging Product Line, Accelerating Expansion into Asia&#039;s Premium Regenerative Medicine Market - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/visionary-holdings-nasdaq-gv-launches-stem-cell-based-anti-aging-product-line-accelerating-expansion-into-asias-premium-regenerative-medicine-market\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Visionary Holdings (Nasdaq: GV) Launches Stem Cell-Based Anti-Aging Product Line, Accelerating Expansion into Asia&#039;s Premium Regenerative Medicine Market - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire HONG KONG , Nov. 10, 2025 \/PRNewswire\/ &#8212;\u00a0Visionary Holdings Inc. (&#8220;GV&#8221; or the &#8220;Company&#8221;), a technology-driven multinational enterprise listed on Nasdaq (Nasdaq: GV), today announced that its wholly owned subsidiary, Visionary Health Technology Group Limited, has official launch of its medical-grade stem cell anti-aging product line, initially targeting the Chinese mainland and broader Asian markets. This launch marks a major milestone following\u00a0GV&#8217;s entry into the stem cell and medical aesthetics sector earlier this year, as well as its strategic partnership and global technology licensing agreement with Jiangsu Yike Regenerative Medicine Co., Ltd. (&#8220;Yike&#8221;), advancing the Company&#8217;s commercialization in regenerative medicine. Core Product Lines and Innovative Value Model GV&#8217;s anti-aging product portfolio includes three major categories: Comprehensive Regenerative Package &hellip; Continue reading &quot;Visionary Holdings (Nasdaq: GV) Launches Stem Cell-Based Anti-Aging Product Line, Accelerating Expansion into Asia&#8217;s Premium Regenerative Medicine Market&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/visionary-holdings-nasdaq-gv-launches-stem-cell-based-anti-aging-product-line-accelerating-expansion-into-asias-premium-regenerative-medicine-market\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-11T00:48:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=CN20006&amp;sd=2025-11-10\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/visionary-holdings-nasdaq-gv-launches-stem-cell-based-anti-aging-product-line-accelerating-expansion-into-asias-premium-regenerative-medicine-market\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/visionary-holdings-nasdaq-gv-launches-stem-cell-based-anti-aging-product-line-accelerating-expansion-into-asias-premium-regenerative-medicine-market\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Visionary Holdings (Nasdaq: GV) Launches Stem Cell-Based Anti-Aging Product Line, Accelerating Expansion into Asia&#8217;s Premium Regenerative Medicine Market\",\"datePublished\":\"2025-11-11T00:48:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/visionary-holdings-nasdaq-gv-launches-stem-cell-based-anti-aging-product-line-accelerating-expansion-into-asias-premium-regenerative-medicine-market\\\/\"},\"wordCount\":816,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/visionary-holdings-nasdaq-gv-launches-stem-cell-based-anti-aging-product-line-accelerating-expansion-into-asias-premium-regenerative-medicine-market\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/edge.prnewswire.com\\\/c\\\/img\\\/favicon.png?sn=CN20006&amp;sd=2025-11-10\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/visionary-holdings-nasdaq-gv-launches-stem-cell-based-anti-aging-product-line-accelerating-expansion-into-asias-premium-regenerative-medicine-market\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/visionary-holdings-nasdaq-gv-launches-stem-cell-based-anti-aging-product-line-accelerating-expansion-into-asias-premium-regenerative-medicine-market\\\/\",\"name\":\"Visionary Holdings (Nasdaq: GV) Launches Stem Cell-Based Anti-Aging Product Line, Accelerating Expansion into Asia's Premium Regenerative Medicine Market - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/visionary-holdings-nasdaq-gv-launches-stem-cell-based-anti-aging-product-line-accelerating-expansion-into-asias-premium-regenerative-medicine-market\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/visionary-holdings-nasdaq-gv-launches-stem-cell-based-anti-aging-product-line-accelerating-expansion-into-asias-premium-regenerative-medicine-market\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/edge.prnewswire.com\\\/c\\\/img\\\/favicon.png?sn=CN20006&amp;sd=2025-11-10\",\"datePublished\":\"2025-11-11T00:48:39+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/visionary-holdings-nasdaq-gv-launches-stem-cell-based-anti-aging-product-line-accelerating-expansion-into-asias-premium-regenerative-medicine-market\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/visionary-holdings-nasdaq-gv-launches-stem-cell-based-anti-aging-product-line-accelerating-expansion-into-asias-premium-regenerative-medicine-market\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/visionary-holdings-nasdaq-gv-launches-stem-cell-based-anti-aging-product-line-accelerating-expansion-into-asias-premium-regenerative-medicine-market\\\/#primaryimage\",\"url\":\"https:\\\/\\\/edge.prnewswire.com\\\/c\\\/img\\\/favicon.png?sn=CN20006&amp;sd=2025-11-10\",\"contentUrl\":\"https:\\\/\\\/edge.prnewswire.com\\\/c\\\/img\\\/favicon.png?sn=CN20006&amp;sd=2025-11-10\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/visionary-holdings-nasdaq-gv-launches-stem-cell-based-anti-aging-product-line-accelerating-expansion-into-asias-premium-regenerative-medicine-market\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Visionary Holdings (Nasdaq: GV) Launches Stem Cell-Based Anti-Aging Product Line, Accelerating Expansion into Asia&#8217;s Premium Regenerative Medicine Market\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Visionary Holdings (Nasdaq: GV) Launches Stem Cell-Based Anti-Aging Product Line, Accelerating Expansion into Asia's Premium Regenerative Medicine Market - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/visionary-holdings-nasdaq-gv-launches-stem-cell-based-anti-aging-product-line-accelerating-expansion-into-asias-premium-regenerative-medicine-market\/","og_locale":"en_US","og_type":"article","og_title":"Visionary Holdings (Nasdaq: GV) Launches Stem Cell-Based Anti-Aging Product Line, Accelerating Expansion into Asia's Premium Regenerative Medicine Market - Market Newsdesk","og_description":"PR Newswire HONG KONG , Nov. 10, 2025 \/PRNewswire\/ &#8212;\u00a0Visionary Holdings Inc. (&#8220;GV&#8221; or the &#8220;Company&#8221;), a technology-driven multinational enterprise listed on Nasdaq (Nasdaq: GV), today announced that its wholly owned subsidiary, Visionary Health Technology Group Limited, has official launch of its medical-grade stem cell anti-aging product line, initially targeting the Chinese mainland and broader Asian markets. This launch marks a major milestone following\u00a0GV&#8217;s entry into the stem cell and medical aesthetics sector earlier this year, as well as its strategic partnership and global technology licensing agreement with Jiangsu Yike Regenerative Medicine Co., Ltd. (&#8220;Yike&#8221;), advancing the Company&#8217;s commercialization in regenerative medicine. Core Product Lines and Innovative Value Model GV&#8217;s anti-aging product portfolio includes three major categories: Comprehensive Regenerative Package &hellip; Continue reading \"Visionary Holdings (Nasdaq: GV) Launches Stem Cell-Based Anti-Aging Product Line, Accelerating Expansion into Asia&#8217;s Premium Regenerative Medicine Market\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/visionary-holdings-nasdaq-gv-launches-stem-cell-based-anti-aging-product-line-accelerating-expansion-into-asias-premium-regenerative-medicine-market\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-11T00:48:39+00:00","og_image":[{"url":"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=CN20006&amp;sd=2025-11-10","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/visionary-holdings-nasdaq-gv-launches-stem-cell-based-anti-aging-product-line-accelerating-expansion-into-asias-premium-regenerative-medicine-market\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/visionary-holdings-nasdaq-gv-launches-stem-cell-based-anti-aging-product-line-accelerating-expansion-into-asias-premium-regenerative-medicine-market\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Visionary Holdings (Nasdaq: GV) Launches Stem Cell-Based Anti-Aging Product Line, Accelerating Expansion into Asia&#8217;s Premium Regenerative Medicine Market","datePublished":"2025-11-11T00:48:39+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/visionary-holdings-nasdaq-gv-launches-stem-cell-based-anti-aging-product-line-accelerating-expansion-into-asias-premium-regenerative-medicine-market\/"},"wordCount":816,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/visionary-holdings-nasdaq-gv-launches-stem-cell-based-anti-aging-product-line-accelerating-expansion-into-asias-premium-regenerative-medicine-market\/#primaryimage"},"thumbnailUrl":"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=CN20006&amp;sd=2025-11-10","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/visionary-holdings-nasdaq-gv-launches-stem-cell-based-anti-aging-product-line-accelerating-expansion-into-asias-premium-regenerative-medicine-market\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/visionary-holdings-nasdaq-gv-launches-stem-cell-based-anti-aging-product-line-accelerating-expansion-into-asias-premium-regenerative-medicine-market\/","name":"Visionary Holdings (Nasdaq: GV) Launches Stem Cell-Based Anti-Aging Product Line, Accelerating Expansion into Asia's Premium Regenerative Medicine Market - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/visionary-holdings-nasdaq-gv-launches-stem-cell-based-anti-aging-product-line-accelerating-expansion-into-asias-premium-regenerative-medicine-market\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/visionary-holdings-nasdaq-gv-launches-stem-cell-based-anti-aging-product-line-accelerating-expansion-into-asias-premium-regenerative-medicine-market\/#primaryimage"},"thumbnailUrl":"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=CN20006&amp;sd=2025-11-10","datePublished":"2025-11-11T00:48:39+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/visionary-holdings-nasdaq-gv-launches-stem-cell-based-anti-aging-product-line-accelerating-expansion-into-asias-premium-regenerative-medicine-market\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/visionary-holdings-nasdaq-gv-launches-stem-cell-based-anti-aging-product-line-accelerating-expansion-into-asias-premium-regenerative-medicine-market\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/visionary-holdings-nasdaq-gv-launches-stem-cell-based-anti-aging-product-line-accelerating-expansion-into-asias-premium-regenerative-medicine-market\/#primaryimage","url":"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=CN20006&amp;sd=2025-11-10","contentUrl":"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=CN20006&amp;sd=2025-11-10"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/visionary-holdings-nasdaq-gv-launches-stem-cell-based-anti-aging-product-line-accelerating-expansion-into-asias-premium-regenerative-medicine-market\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Visionary Holdings (Nasdaq: GV) Launches Stem Cell-Based Anti-Aging Product Line, Accelerating Expansion into Asia&#8217;s Premium Regenerative Medicine Market"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/907960","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=907960"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/907960\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=907960"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=907960"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=907960"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}